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Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by articular inflammation and
systemic complications. Multimorbidity (the presence of two or more long-term health conditions) is highly prevalent in
people with RA but the effect of multimorbidity on mortality and other health-related outcomes is poorly understood.
Objective: To determine what is known about the effect, if any, of multimorbidity on mortality and health-related out-
comes in individuals with RA.
Design: Systematic review of the literature. The following electronic medical databases will be searched: MEDLINE,
Embase, Cumulative Index to Nursing and Allied Health Literature, PsycINFO, The Cochrane Library and Scopus.
Included studies will be quality appraised using the Quality in Prognostic Studies tool developed by the Cochrane
Prognosis Methods Group. A narrative synthesis of findings will be undertaken and meta-analyses considered, if appro-
priate. This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols 2015
guidelines, ensuring the quality of the review.
Conclusions: Understanding the influence of multimorbidity on mortality and other health-related outcomes in RA will
provide an important basis of knowledge with the potential to improve future clinical management of RA. PROSPERO
registration number: CRD42019137756.
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Introduction
Rationale
Rheumatoid arthritis (RA) is the most prevalent inflamma-
tory arthropathy, affecting 0.5–1.0% of the adult population
in developed countries.1 In RA, persistent autoimmune-
mediated inflammation causes pain, swelling, tenderness
and destruction of synovial joints which is associated with
functional disability and reduced quality of life.2 High eco-
nomic costs and increased morbidity and mortality are
often a consequence of RA and contribute substantially to
the overall burden of disease at both patient and healthcare
1General Practice and Primary Care, Institute of Health and Wellbeing,
College of Medical, Veterinary and Life Sciences, University of Glasgow,
Glasgow, UK
2 Institute of Infection, Immunity and Inflammation, College of Medical,
Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
Corresponding author:
Jordan Canning, General Practice and Primary Care, Institute of Health
and Wellbeing, College of Medical, Veterinary and Life Sciences,




ª The Author(s) 2020
DOI: 10.1177/2235042X20906657
journals.sagepub.com/home/cob
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License
(https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/
open-access-at-sage).
level.3 The management of RA has been transformed in
recent decades by the optimal use of disease-modifying
anti-rheumatic drugs and the availability of targeted biolo-
gical treatments.4 However, the presence of concurrent
long-term conditions (LTCs) can cause additional compli-
cations in individuals with RA.5 Common comorbid LTCs
include cardiovascular disease, osteoporosis and depres-
sion, with the average RA patient having 1.6 additional
LTCs; this number increases with age, disease duration and
disease activity. It is estimated that multimorbidity (the co-
existence of two or more LTCs) is present in approximately
two-thirds of people with RA.6 Multimorbidity itself has
been linked to excess mortality, increased healthcare utili-
sation and poorer quality of life.7,8 However, the relation-
ship between RA and multimorbidity is poorly understood.
Likewise, the effects of this relationship on mortality and
other health-related outcomes remain unclear. Examining
such relationships will provide a valuable foundation to
support future patient care through greater understanding
of those at increased risk of adverse health-related
outcomes.
Objectives
This systematic review will appraise the literature to deter-
mine what is known about the effect, if any, of multimor-
bidity on mortality and other health-related outcomes in
individuals with RA.
Methods
The Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) 2015 reporting
guidelines were used to prepare this protocol (Online Sup-
plementary File S1).9,10
Eligibility criteria
Inclusion and exclusion criteria are summarised in Table 1.
Study design. Empirical studies using quantitative methods
will be eligible for our review. We will expressly target
longitudinal cohort studies (both retrospective and prospec-
tive). Cross-sectional studies, intervention studies, qualita-
tive studies, case reports/series and review articles
(including systematic reviews) will be excluded. There will
be no restriction on the publication date of included studies
in the systematic review, with a search end date of 6
December 2018.
Population. Studies must involve adults (18 years or older)
with RA and two or more other physical or mental health
LTCs. Studies involving children/adolescents (under
18 years) or animals will be excluded.
Exposure. The exposure of interest is the presence of two or
more LTCs in adults with RA. We will include studies that
assess the relationship between RA, multimorbidity and our
outcomes of interest using any numerical count of comor-
bidity/multimorbidity, where the type of comorbid condi-
tions is also specified. Studies that focus solely on one
comorbid condition with RA will be excluded as this sys-
tematic review is only interested in the relationship
between RA and multimorbidity.
Comparators. Participants with only RA and no other LTCs
or those with RA and one other LTC will act as the com-
parator/control group. However, studies that do not include
a comparator/control group will not be excluded.
Outcomes. The primary outcome will be all-cause mortality.
Health-related outcomes will also be of interest, particu-
larly those relating to disability and quality of life. Of inter-
est, are those reported by patients regarding their
emotional, social and physical wellbeing via health assess-
ment questionnaires (HAQ) and/or patient-reported out-
come measures. Studies which provide data on any of
these outcomes will be included.
Publication type. Studies must be full-text published articles.
Conference abstracts, dissertations/theses and editorials/
commentaries/letters will be excluded.
Language. Studies must be in the English language.
Table 1. Summary of inclusion and exclusion criteria to be used during the study selection process.
Category Inclusion criteria Exclusion criteria
Study design Longitudinal cohort studies (retrospective
and prospective)
Cross-sectional studies; intervention studies; qualitative studies;
case reports/series; review articles (including systematic reviews)
Population Adults (18 years or older) Children/adolescents (under 18 years); animal studies
Exposure RA þ 2 LTCs RA þ 1 LTC
Comparator RA þ 1 LTC None
Outcomes Mortality and/or health-related outcomes
Publication type Full-text published article Conference abstracts; dissertations/theses; editorials/commentaries/
letters
Language English language Non-English language
RA: rheumatoid arthritis; LTC: long-term condition.
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Information sources
The following electronic medical databases will be
searched: MEDLINE (Ovid), Embase (Ovid), Cumulative
Index to Nursing and Allied Health Literature (CINAHL;
EBSCOhost), PsycINFO (EBSCOhost), The Cochrane
Library (Central Register of Controlled Trials (CEN-
TRAL); Wiley) and Scopus (Elsevier). The International
Prospective Register of Systematic Reviews (PROSPERO)
will be monitored for other ongoing and completed sys-
tematic reviews on RA and multimorbidity.
Search strategy
The search strategy will combine the following concepts:
(1) RA, (2) comorbidity/multimorbidity, (3) mortality and
(4) health-related outcomes (see ‘Outcomes’ section),
using subject index terms and keywords (Table 2). Each
database will be searched individually with the search
strategy adapted to reflect the differing subject index
terms and keywords used by each database. Advanced
search features, such as multi-field search, operators, trun-
cation/wildcards and limits, will be combined with the
appropriate Boolean terms to create our search strategy.
This search strategy will be reviewed by the University of
Glasgow College Librarian for Medical, Veterinary and
Life Sciences and members of our review panel with
expertise in RA and multimorbidity (Online Supplemen-
tary File S2).
Study records
Data management. The results of the literature search will
be downloaded to EndNote (X7.7.1; Thomson Reuters) and
duplicates removed. The remaining studies will be
uploaded to the systematic review management software,
DistillerSR (Evidence Partners, Ontario, Canada), in pre-
paration for the selection process.
Selection process. The process for selecting eligible studies
will be conducted in two stages, namely title/abstract
screening and full-text screening. Titles and abstracts of
studies identified from the database searches will be
screened independently by the primary researcher (JC) and
another member of the review team (SS, BJ, FM or BN)
against predefined eligibility criteria. Studies that meet the
eligibility criteria will undergo full-text screening. Con-
flicting studies will also undergo full-text screening. Full-
text articles will be obtained and the primary researcher
(JC) and one other reviewer (SS, BJ, FM or BN) will again
independently review studies against the predefined elig-
ibility criteria. Online supplementary material will be con-
sulted when necessary to support the decision-making
process. Disagreements at this stage will be resolved by
discussion and/or consultation with a third reviewer. A
citation search will also be performed on full-text articles
to identify any additional relevant studies.
Data collection process. Data from included studies will be
extracted and recorded in a predefined data extraction form
designed by the primary researcher (JC), as per Cochrane
Handbook recommendations, specifically the Cochrane
PICO statement where Intervention (‘I’) is replaced with
Exposure (‘E’). The form will cover Population, Exposure,
Comparator and Outcomes (Table 1). Study characteristics
will also be included to record study design, setting, study
time period and aims and objectives. The data extraction
form will be piloted and any modifications to the form will
be made by the review team. Data extraction will be carried
out in duplicate by independent reviewers and discrepan-
cies will be resolved by discussion and/or consultation with
a third reviewer.
Data items
Study characteristics. Details relating to study design, setting,
period of study and study aims and objectives will be
extracted.
Population. Study population characteristics, such as sample
size, sex, age, ethnicity, sociodemographic status, occupa-
tion, education, RA duration and treatment, will be
Table 2. Summary of subject index terms and keywords used in search strategy and adapted for each electronic medical database.
Key concepts Rheumatoid arthritis Multimorbidity Mortality Health-related outcomes
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extracted. RA definition/diagnosis criteria will be noted.
Population recruitment and sampling for each study will
be recorded, as will the individual inclusion/exclusion
criteria.
Exposure. The definition/measure of multimorbidity and
number/type of comorbid conditions will be reported for
each included study.
Comparator.Details of comparator/control groups including
definition/measure of participants with RA and no/one
other LTCs will be extracted.
Outcome. We will record how all-cause mortality and
health-related outcomes are defined and measured by each
included study. Length of follow-up and statistical analyses
used by the authors to evaluate the relationship between
RA, multimorbidity and mortality or health-related out-
comes will be extracted.
Statistical methods. We will also record the statistical meth-
ods used, reported results, nature of association reported
along with the corresponding effect sizes and adjusting
confounders used in the model.
Outcomes and prioritisation
The primary outcome of interest is all-cause mortality
which may be calculated as hazard ratios, odds ratios, inci-
dence rates or survival percentages. Health-related out-
comes may be clinician- and/or patient-reported via
appropriate questionnaires, for example, HAQ, patient/
physician global assessment and short form 36.
Risk of bias in individual studies
The Quality in Prognostic Studies tool (developed by the
Cochrane Prognosis Methods Group) will be used by two
reviewers (JC and SS, BJ, FM or BN) to independently
assess risk of bias within included studies. Judgements will
be made for each of the following domains: Study Partic-
ipation, Study Attrition, Prognostic Factor Measurement,
Outcome Measurement, Study Confounding and Statistical
Analysis and Reporting. Each domain will be assigned a
‘Rating of “Risk of bias”’ as either ‘High’, ‘Moderate’ or
‘Low’. The adequacy of reporting will be rated as ‘Yes’,
‘Partial’, ‘No’ or ‘Unsure’. Text comments to facilitate the
consensus process will also be included, as necessary. Dis-
agreements between reviewers at this stage will be dis-
cussed and resolved by a third reviewer, if required.
Data synthesis
Included studies will be grouped together according to out-
comes in preparation for data synthesis. A narrative synth-
esis of findings will be conducted which will describe the
following from each included study: study characteristics,
population, exposure, comparator, outcomes, risk of bias
(quality) assessment and study inconsistencies, if any. If
appropriate, a meta-analysis will be conducted with tests
for publication bias and heterogeneity carried out before-
hand. No analysis of subgroups or subsets is planned at
present. However, this decision will be re-assessed depend-
ing on findings. If appropriate, separate analyses may be
conducted on relevant study population characteristics, for
example, age, gender, socioeconomic status or multimor-
bidity count/type of comorbid conditions.
Ethics approval and dissemination
This systematic review will not contain individual patient
data therefore ethics approval is not required. The results of
this review will be disseminated via relevant scientific con-
ferences, peer-reviewed publications and social media.
This review also fulfils objectives of the primary research-
er’s (JC) Doctoral Training Programme (DTP) project.
Discussion
This systematic review will evaluate the existing literature
to determine what is known about the effect of multimor-
bidity on mortality and adverse health-related outcomes in
people with RA. We expect to find multimorbidity to be
associated with excess mortality, worsened functional sta-
tus and reduced quality of life in individuals with RA. We
also anticipate that differing numbers and types of comor-
bid LTCs will have varying impacts on these outcomes.
This systematic review will be the first to our knowledge
to examine the current information available to delineate
such relationships, identify gaps in knowledge and contrib-
ute to overall understanding in this area. Identifying areas
for additional investigation may further bridge the gap
between current understanding and future clinical guide-
line/health service design modifications.
This systematic review has several key strengths includ-
ing adhering to PRISMA-P 2015 guidelines to ensure
clarity and transparency in our reporting. We will also
develop a comprehensive search strategy with guidance
from a specialist librarian to minimise the omission of rel-
evant studies. Likewise, all screening and data extraction
will be performed independently by two reviewers to limit
any oversights.
The definition of multimorbidity and the reporting of
outcomes in literature are expected to vary considerably.
A narrative synthesis of findings may therefore be con-
ducted to accommodate the heterogeneous nature of the
literature which is a potential limitation. The search strat-
egy also restricts publications to English language only
which is a possible limitation, although it has previously
been suggested that this is not a major drawback to the
quality of a systematic review.11
Without a defined relationship between RA and multi-
morbidity, it is difficult to develop and implement
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standardised treatment advice and guidelines that are inclu-
sive to RA patients with multimorbidity. Enhanced under-
standing of RA and multimorbidity may therefore help to
identify those at increased risk of experiencing adverse
clinical and health-related outcomes, with potential impli-
cations for future clinical practice.
Acknowledgement
We acknowledge the contributions of Paul Cannon (University of
Glasgow College Librarian for Medical, Veterinary and Life
Sciences) for assisting with the development of the search
strategy.
Author contributions
All authors (JC, SS, BJ, FM and BN) contributed to the develop-
ment of the search strategy, inclusion/exclusion criteria and data
extraction form. Protocol was drafted by JC and reviewed and
edited by SS, BJ, FM and BN. All authors have approved the final
manuscript for submission.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: This work is supported by the Medical Research Council
(MRC) [grant number: MR/N013166/1]; Dr Bhautesh Jani’s NRS





Supplemental material for this article is available online.
References
1. Scott DL, Wolfe F and Huizinga TWJ. Rheumatoid arthritis.
Lancet 2010; 376(9746): 1094–1108.
2. Calabresi E, Petrelli F, Bonifacio AF, et al. One year in
review 2018: pathogenesis of rheumatoid arthritis. Clin Exp
Rheumatol 2018; 36(2): 175–184.
3. Cooper NJ. Economic burden of rheumatoid arthritis: a sys-
tematic review. Rheumatology 2000; 39(1): 28–33.
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid
arthritis classification criteria: an American college of
rheumatology/European league against rheumatism colla-
borative initiative. Arthritis Rheum 2010; 62(9):
2569–2581.
5. Nakajima A, Inoue E, Shimizu Y, et al. Presence of comor-
bidity affects both treatment strategies and outcomes in dis-
ease activity, physical function, and quality of life in patients
with rheumatoid arthritis. Clin Rheumatol 2015; 34(3):
441–449.
6. Radner H. Multimorbidity in rheumatic conditions.Wien Klin
Wochenschr 2016; 128(21-22): 786–790.
7. Jani BD, Hanlon P, Nicholl BI, et al. Relationship between
multimorbidity, demographic factors and mortality: find-
ings from the UK biobank cohort. BMC Medicine 2019;
17: 74.
8. Simo˜es D, Arau´jo FA, Severo M, et al. Patterns and conse-
quences of multimorbidity in the general population: there is
no chronic disease management without rheumatic disease
management. Arthrit Care Res 2017; 69(1): 12–20.
9. Shamseer L, Moher D, Clarke M, et al. Preferred reporting
items for systematic review and meta-analysis protocols
(PRISMA-P) 2015: elaboration and explanation. BMJ 2015;
349: g7647.
10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting
items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1.
11. Morrison A, Polisena J, Husereau D, et al. The effect of
English-language restriction on systematic review-based
meta-analyses: a systematic review of empirical studies.
Int J Technol Assess Health Care 2012; 28(2): 138–144.
Canning et al. 5
